ð ç« æ«éèš
- PJP: Pneumocystis jirovecii â fungus (renamed from carinii)
- Risk: HIV CD4 < 200 (#1), transplant, anti-CD20, corticosteroids, chemo, anti-TNF
- Clinical: insidious dry cough + dyspnea + hypoxia + low fever; bilateral perihilar interstitial CXR / ground-glass HRCT
- Lab: β-D-glucan elevated, elevated LDH, lymphopenia (HIV), hypoxia, A-a gradient
- Diagnosis: BAL + immunofluorescence (gold standard); induced sputum (less sensitive)
- Treatment: TMP-SMX 15-20 mg/kg/d à 21 days
- Steroid if A-a > 35 / PaO2 < 70: prednisone 40 bid à 5 â 40 qd à 5 â 20 qd à 11 days (reduces mortality)
- Alternatives: clinda + primaquine (G6PD), pentamidine IV, atovaquone PO, TMP + dapsone (G6PD)
- Prophylaxis:
- HIV CD4 < 200: TMP-SMX 1 DS qd
- Transplant: 6-12 mo post
- Anti-CD20: case-by-case
- Stop HIV: CD4 > 200 Ã 3-6 mo on ART
- HIV-PJP: insidious + steroid critical; start ART within 2 weeks
- Non-HIV-PJP: rapid onset + higher mortality
ç§é«åž« hint
- HIV CD4 < 200 + dry cough + hypoxia â empirical TMP-SMX
- Transplant + immunocompromise + bilateral ground-glass â consider PJP
- TMP-SMX intolerance â clindamycin + primaquine (G6PD screen)
- Pre-immunosuppression: consider PJP prophylaxis (TMP-SMX) for high-risk regimens